

Risk Assessment Blood and Body Fluid Exposure Central Zone

Last Name (Legal)			First Name (Legal)				
Preferred Name	ast 🗆 First 🛛 DOE		DOB	(dd-Mon-yyyy)			
PHN	ULI 🗆 Sa	ame a	s PHN	MRN			
Administrative Gender Male Female							

AHS Staff	HS Staff call 1-855-450-3619					1	Refer
Did the							assessment to
exposure occur Yes Covenant	-Yes• Covenant Staff call 1-855-342-8070						WHS/OHS
	All Other Employer Name: Phone:						
	No Employee Occupation:						
Continue assessment below	·		_				
General Exposure Information							
Date of Exposure (dd-Mon-yyyy)		Time of Exposu	re (hh:mm)	Patie	nt Phor	ne N	umber
Was the Patient exposed to blood, blo mucous membranes?	ood-containing	j body fluid, sem	nen or va	ginal fluid	d via br	oker	skin or on
🗆 No → No Risk - discontinue thi	s assessment						
□ Yes → Choose type of exposure	e from the 4 o	ptions below:					
Visible Blood <i>(fresh on device/s</i> Depth of Injury Duperfic	re □ Other y <i>ringe)</i> □ No ial □ Deep j	 → of fluid → (Sharp) □ Yes puncture 	 ▶ □ em □ sali □ vaç □ ser □ urir □ oth 	esis with va/sputu	wisible with with	bloc visib	le blood blood
Details of Exposure (Location, other pe	rtinent informat	ion)					
Source Risk Assessment							
Is source known? □ Yes →	Name				DOB	dd-N	Лоп-уууу)
□ No (skip section)							
ULI	Contact Pho	ne		Other Pl	hone		
If present at the time of assessment,	is source willir	ng to be tested?		⊐ No		es	
Risk Factors							
Source known to be positive for	Hepatitis B	□ Hepatitis	С	□ HIV	0	⊐ Un	known
Presence of symptoms consistent (fever, headache, rash, lymphadenopa					Нер С		
□ Source has used IV drugs		Source has used	d non-IV	drugs <i>(sr</i>	norting, s	sharii	ng pipes)
□ History of incarceration □ Other risk	 Multiple sexual partners or sex with sex trade workers None identified 						



Low Risk Assessment Information

Assessing the risk of transmission of blood borne diseases includes consideration of both the risk that the source is infected/infectious and the risk carried by the exposure. Some examples of lower risk exposure to blood borne pathogens would include, but are not limited to:

- Source has no risk factors
- Solid bore percutaneous injury has less risk than hollow bore
- · Superficial injury has less risk than deep injury
- Mucous membrane exposure to small volume blood or visible blood-stained bodily fluids has less risk than large volume of frank blood on mucous membranes

Published literature indicates the following probabilities of blood borne pathogen transmission in various scenarios when the source is known to be infected by the following pathogens:

HIV

- Injection drug use 1/150
- Needlestick (health care) 1/333 *Note:* There have been no reported instances of transmission of HIV from needles found incidentally in the community outside of health care settings.
- Receptive anal intercourse 1/100 to 1/3
- Insertive anal intercourse 1/1000 to 1/10
- Receptive vaginal exposure 1/1000 to 1/10

Hepatitis B

- Needlestick (health care) 37-62%
- · Sexual exposure is estimated to be transmitted 8.6 fold more efficiently than HIV

Hepatitis C

- Needlestick (health care) 1.8%
- Transmission sexually is very low, but is higher with multiple sexual partners or if blood is present

_		Last Name	(Legal)	First Nam	1e (Legal)		
Alberta Health							
Services					st DOB(dd-Mon-yyyy)		
Risk Assessment Blood and Body Fluid Exp Central Zone	osure		tive Gender □ M		MRN Female Unknown		
Immunization Status							
Hepatitis B Immunization	commer	nded lab tes	ting section b	elow.			
	commer HBsAb r Yes, Hep	esult greate B testing o	er than or equ	ual to 1(d source	e not required		
Consultation (if applicable) and HIV PEP Approval							
 If exposure risk assessment is low (see bottom of page 1 a For consulations and/or HIV PEP approval, contact: Daily between 08:30 and 16:00 hrs Provincial Communicable Disease Control Intake 	• After	hours: Daily	v between 16:	:00 and (08:30 hrs.		
Pager: 1 (833) 493-8822		Medical Officer of Health (MOH) On-Call Phone: (403) 356-6430					
A CDC nurse will follow-up on serology results if you fax th	is form to	o (403) 356-	2053				
 If the exposed patient lives on a First Nations reserve, cont First Nations and Inuit Health Branch (FNIHB) MOH on MOH/CDC Nurse consulted Last Name, First Name 		ohone: (780)	218-9929 Date (dd-Mor		Time (hh:mm		
				* }}}/			
 HIV PEP released by MOH/CDC Kit 1: tenofovir/emtricitabine (Truvada®) and Kit 2: tenofovir/emtricitabine (Truvada®) and Other HBIG & Hep B Vaccine Recommended 		•	• /	navir (No	orvir®)		
Recommended Laboratory Testing							
Recipient		Source					
□ Hepatitis B antibody (HBs Ab) □ Hepatitis B antigen (HBs Ag)		□ Hepatitis B antigen (HBs Ag) Order only if <i>recipient</i> has no serology, or not					
 Hepatitis C antibody (HCV Ab) HIV antibody (HIV Ab) 		immune					
If given HIV PEP, order □ CBC □ Creatinine □ HCG	□ Hepatitis C antibody (HCV Ab) □ HIV antibody (HIV Ab)						
For Sexual Assaults order □ Gonorrhea □ Chlamydia □ Trichomonas □ Syp	hilis						
You can find a completed lab test requisition example at	www.al	ns.ca/czmoł	า.				
Assessment Completed by:							
Last Name F	First Nar	me					
Signature		C	Date (dd-Mon-yy	уу)	Time (hh:mm)		
Resources							
For more information refer to the <i>BBFE Know the Facts</i>	Brochur	e at www.al	hs.ca/czmoh				

FAX completed form to Central Zone CDC **403-356-2053** to enable patient follow up on baseline serology. 20443(Rev2022-11) Page 2 of 2